Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million

Reuters03-19

Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million

Sol-Gel published its annual report on Form 20-F for the year ended Dec. 31, 2025.
Revenue rose 68.05% to USD 19.39 million, mainly from milestone payments tied to the Mayne and Searchlight agreements.
Net loss narrowed 42.09% to USD 6.13 million, while R&D expense increased 28.1% to USD 22.8 million.
Cash and cash equivalents, bank deposits and marketable securities were USD 12.4 million as of Dec. 31, 2025, and management said this is expected to fund operations into the first quarter of 2027.
Enrollment was completed in August 2025 in Sol-Gel’s Phase 3 SGT-610 (patidegib gel 2%) trial in Gorlin syndrome, with topline results expected in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001552), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620099228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620099228","market":"nz","top_or_hot":-1,"title":"Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sol-Gel published its annual report on Form 20-F for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 68.05% to USD 19.39 million, mainly from milestone payments tied to the Mayne and Searchlight agreements.\n        </li>\n<li>\n          Net loss narrowed 42.09% to USD 6.13 million, while R&amp;D expense increased 28.1% to USD 22.8 million.\n        </li>\n<li>\n          Cash and cash equivalents, bank deposits and marketable securities were USD 12.4 million as of Dec. 31, 2025, and management said this is expected to fund operations into the first quarter of 2027.\n        </li>\n<li>\n          Enrollment was completed in August 2025 in Sol-Gel’s Phase 3 SGT-610 (patidegib gel 2%) trial in Gorlin syndrome, with topline results expected in the fourth quarter of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001552), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 20:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sol-Gel published its annual report on Form 20-F for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 68.05% to USD 19.39 million, mainly from milestone payments tied to the Mayne and Searchlight agreements.\n        </li>\n<li>\n          Net loss narrowed 42.09% to USD 6.13 million, while R&amp;D expense increased 28.1% to USD 22.8 million.\n        </li>\n<li>\n          Cash and cash equivalents, bank deposits and marketable securities were USD 12.4 million as of Dec. 31, 2025, and management said this is expected to fund operations into the first quarter of 2027.\n        </li>\n<li>\n          Enrollment was completed in August 2025 in Sol-Gel’s Phase 3 SGT-610 (patidegib gel 2%) trial in Gorlin syndrome, with topline results expected in the fourth quarter of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001552), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1F4ZYt:1","article_id":"2620099228","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620099228","pubTimestamp":1773924836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sol-Gel published its annual report on Form 20-F for the year ended Dec. 31, 2025.Revenue rose 68.05% to USD 19.39 million, mainly from milestone payments tied to the Mayne and Searchlight agreements.Net loss narrowed 42.09% to USD 6.13 million, while R&D expense increased 28.1% to USD 22.8 million.Cash and cash equivalents, bank deposits and marketable securities were USD 12.4 million as of Dec. 31, 2025, and management said this is expected to fund operations into the first quarter of 2027.Enrollment was completed in August 2025 in Sol-Gel’s Phase 3 SGT-610  trial in Gorlin syndrome, with topline results expected in the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the orig","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SLGL":"Sol-Gel Technologies"},"translate_title":"Sol-Gel 2025财年净亏损收窄42.08%至613万美元，收入增长68.06%至1939万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLGL":0.9},"content_text":"Sol-Gel FY 2025 net loss narrows 42.08% to USD 6.13 million on revenue up 68.06% to USD 19.39 million\n    \n\n\n          Sol-Gel published its annual report on Form 20-F for the year ended Dec. 31, 2025.\n        \n\n          Revenue rose 68.05% to USD 19.39 million, mainly from milestone payments tied to the Mayne and Searchlight agreements.\n        \n\n          Net loss narrowed 42.09% to USD 6.13 million, while R&D expense increased 28.1% to USD 22.8 million.\n        \n\n          Cash and cash equivalents, bank deposits and marketable securities were USD 12.4 million as of Dec. 31, 2025, and management said this is expected to fund operations into the first quarter of 2027.\n        \n\n          Enrollment was completed in August 2025 in Sol-Gel’s Phase 3 SGT-610 (patidegib gel 2%) trial in Gorlin syndrome, with topline results expected in the fourth quarter of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001552), on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620099228","isCrawlerRequest":true}